Overview

First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4011499 in Healthy Participants

Status:
Not yet recruiting
Trial end date:
2023-01-19
Target enrollment:
Participant gender:
Summary
This FTIH study aims to evaluate the safety, tolerability and PK of the novel investigational Human immunodeficiency virus (HIV)-1 capsid inhibitor VH4011499 in healthy adults. The study will be conducted in 2 parts: Part 1 will investigate single ascending doses (SAD) and Part 2 will investigate multiple ascending doses (MAD). The transition from SAD to MAD will be based on the assessment of the Safety and Dose Escalation Committee.
Phase:
Phase 1
Details
Lead Sponsor:
ViiV Healthcare